Recombinant respiratory syncytial virus particle antigen
Patent Information
- Application Number
- CN202410663777.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-19
- Filing Date
- 2024-05-27
- Publication Date
- 2024-11-26
AI Technical Summary
尽管已有大量关于RSV F蛋白融合前构象稳定性的研究,但其作为疫苗使用的安全性和有效性仍面临巨大的挑战
[0082] By carrying out targeted truncation, reconstruction, stabilization modification, granulation and other designs on the wild-type RSV F protein, the present invention is able to display the RSV F protein that retains specific epitopes for pre-fusion conformation proteins on twelve The particle antigen on the surface of the polymeric nanoparticles maintains the stable pre-fusion conformation and protein loading of F protein while ensuring that it can induce effective neutralizing antibody responses and binding antibody responses to respiratory syncytial virus, with excellent immune response or immunogenicity.
Smart Images

Figure CN119019566A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of biomedicine technology, and in particular relates to a recombinant respiratory syncytial virus particle antigen and a preparation method thereof, and an application thereof in the preparation of a vaccine for preventing RSV infection. Background Art
[0002] Respiratory viral infections are one of the most important public health burdens worldwide, resulting in millions of hospitalizations worldwide each year. Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in children under 2 years of age and adults over 65 years of age. Despite the serious harm caused by respiratory diseases caused by RSV infection, there are currently few effective treatments and preventive vaccines specifically for RSV. Looking at the RSV vaccines that have entered the clinical stage worldwide, the main research and development directions are concentrated on live attenuated vaccines, recombinant subunit vaccines, and viral vector vaccines. RSV vaccine development is mainly aimed at three target groups, including infants, pregnant women, and the elderly (≥60 years old). For infants under 6 months of age, passive immune protection is mainly achieved through mAbs, or passive protection is obtained by antibody transfer through the placenta after pregnant women are vaccinated with RSV vaccines; for infants older than 6 months of age, protection can be obtained through active immunization with live attenuated RSV vaccines; for pregnant women and the elderly, RSV vaccine development is mainly based on subunit vaccines.
[0003] The selection of mainstream vaccine antigens is mainly focused on F protein, especially the F protein in the prefusion conformation (PreF). Compared with the F protein in the postfusion conformation, the F protein in the prefusion conformation can expose more potential epitopes with neutralizing activity, such as epitope Φ and epitope V that only exist in PreF. Antibodies generated against epitope Φ and epitope V have excellent neutralizing activity. After binding to the F protein in the prefusion conformation, they can block the viral membrane fusion mediated by the conformational change of the F protein. Although there have been a lot of studies on the stability of the prefusion conformation of RSV F protein, its safety and effectiveness as a vaccine still face huge challenges.
[0004] Therefore, providing an RSV antigen with high safety, enhanced immunogenicity and improved stability, and a vaccine containing the same has become a technical problem that those skilled in the art urgently need to solve. Summary of the invention
[0005] It is known to those skilled in the art that the F glycoprotein of RSV is highly antigenic and heritable, and has two main conformations on the surface of RSV: an active conformation, i.e., pre-fusion F (pre-F); and an inactive conformation, i.e., post-fusion F (post-F). Pre-F has six major antigenic sites (Φ, Ⅰ, Ⅱ, Ⅲ, Ⅳ and Ⅴ), while post-F has only four (Ⅰ, Ⅱ, Ⅲ and Ⅳ). The latter is more stable but not highly antigenic, while the former is highly antigenic but relatively unstable.
[0006] SiteI is a linear epitope consisting of amino acids 387-392 located between the α8 helix and β14. The antibody that recognizes this epitope is 131-2a, which has poor neutralizing ability.
[0007] The representative antibody that recognizes the site III epitope is MPE8, which prefers to bind to the protein in the pre-F conformation.
[0008] SiteIV is a linear structure consisting of amino acids 422-438 of the wild-type RSV F protein sequence shown in SEQ ID NO:1. The representative antibody of this epitope is 101F, which exhibits moderate neutralizing ability.
[0009] In previous studies, we found that although some F proteins containing all antigenic epitopes that were stabilized in the pre-fusion conformation through stabilization design (for example, proteins in trimer or particle form based on the extracellular domain of the F protein supplemented with stabilizing amino acid modification design) can also be used as immunogens to produce high concentrations of neutralizing antibodies in mice, the presence of antigenic epitopes siteI and siteIV in the stalk region of the pre-F protein resulted in antigenic competition, which reduced the quality of the antibody response to a certain extent.
[0010] In order to solve the above technical problems, the present invention focuses more on being able to fully expose the quaternary epitopes siteΦ and siteⅤ that only exist in the pre-fusion conformation of the RSV F protein, as well as the head domain portion of siteⅡ located in the middle of pre-F, and provides a recombinant respiratory syncytial virus (RSV) particle antigen, which comprises a granulation domain that can self-assemble into a dodecamer and a recombinant head domain of the RSV F protein, wherein the recombinant head domain comprises a truncated fragment of the F1 domain and a truncated fragment of the F2 domain of the RSV F protein directly connected or connected by a linker sequence from the N-terminus to the C-terminus.
[0011] The recombinant head domain in the particle antigens of the present invention has the potential to focus and improve the quality of the antibody response.
[0012] More specifically, the F2 domain truncated fragment in the recombinant head domain of the particle antigen of the present invention is connected to the C-terminus of the F1 domain truncated fragment by direct connection or linker sequence connection, which results in a topological structure different from that of the wild-type RSV F protein. The spatial arrangement of the amino acid residues corresponding to the F2 domain truncated fragment and the F1 domain truncated fragment in the F protein is rearranged, resulting in a tertiary structure with a more compact spatial connection, which greatly increases the stability of the F protein and has an important influence on the function of the F protein. Compared with the wild-type RSV F protein, the recombinant head domain obtained by structural rearrangement can permanently and fully expose the quaternary epitopes siteΦ and siteⅤ that only exist in the pre-fusion conformation of the RSV F protein, as well as siteⅡ in the middle of pre-F, further enhancing the immunoreactivity and immunogenicity.
[0013] Specifically, the recombinant head domain in the particle antigen provided by the present invention contains a highly conserved epitope siteΦ that only exists in the pre-fusion conformation, and the epitope siteΦ is specifically located at the top of the distal membrane end of pre-F. The epitope contains residues 62-69 and 196-209 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1. The representative antibody that recognizes the epitope is D25, and the D25 antibody exhibits a high degree of neutralization ability, and the neutralization titer is almost 100 times that of Palivizumab.
[0014] The recombinant head domain in the particle antigen provided by the present invention also contains an epitope site V that only exists in the pre-fusion conformation. The epitope is a trimer epitope composed of amino acids 146-194 and 287-300 of the wild-type RSV F protein shown in SEQ ID NO: 1. The antibody AM14 that recognizes the epitope can only bind to the two monomer binding regions of pre-F and has a high neutralizing ability.
[0015] The recombinant head domain in the particle antigen provided by the present invention also contains an epitope site II present in both the pre-fusion conformation and the post-fusion conformation, and the epitope is composed of an α6 helix, an α7 helix and a loop therebetween (amino acids 255-276 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1). Representative antibodies that recognize the epitope are Palivizumab and its second-generation antibody Motavizumab, and these antibodies exhibit moderate neutralizing ability.
[0016] In some embodiments, the N-terminus of the particle domain is directly connected to the C-terminus of the recombinant head domain or is connected via a linker sequence.
[0017] In some embodiments, the N-terminus of the granulation domain is connected to the C-terminus of the recombinant head domain via a linker sequence to form a granular antigen in the form of a fusion protein by direct fusion.
[0018] In some embodiments, the C-terminus of the particle domain is directly connected to the N-terminus of the recombinant head domain or is connected via a linker sequence.
[0019] In some embodiments, the C-terminus of the granulation domain is connected to the N-terminus of the recombinant head domain via a linker sequence to form a granular antigen in the form of a fusion protein by direct fusion.
[0020] In some embodiments, optionally, the linker sequence is GGGSSGS, GSGSG, or a 4-10 amino acid sequence consisting of G and S.
[0021] In some specific embodiments, the particle structure domain can self-assemble into a dodecamer. Preferably, the particle structure domain is Dps.
[0022] Dps (DNA protection during starvation) protein is a family of fully conservative proteins found in bacteria and archaea, but it is not present in animals or humans. They are responsible for protecting cell DNA from free radical damage under stress conditions. Dps is a dodecamer nanoparticle composed of 12 identical subunits arranged symmetrically in 2:3. It has a diameter of 9nm, and the inner cavity diameter is 4.5nm (Grant et al., Natural Structure and Molecular Biology (Nat Struct.Biol.) 5:294-303, 1998). The Dps of Escherichia coli (E.Coli) is the prototype of Dps, which was first discovered by Almiron et al. in 1992 (Genes and Development (Genes Dev) 6:2646-2654, 1992). When cells are under stress or starvation conditions, the expression of Dps increases. The molecular weight of each Dps subunit is 20kDa and folds into a tight four-helix bundle with free N- and C-terminals at opposite ends. The four helices are interconnected by three loop sequences of variable length. Short helices can also form in the free N-terminus. Twelve copies of the Dps subunit are assembled into 9 nm nanoparticles according to a 2:3 symmetry, with both the free N- and C-terminal sequences exposed on the surface.
[0023] The crystal structures of Dps from several bacteria and archaea have been determined, including Escherichia coli (Grant et al., Nat Struct. Biol. 5:294–303, 1998), Sulfolobus solfataricus (Gauss et al., Biochemistry, 45:10815-10827, 2006), Mycobacterium smegmatis (Roy et al., J Mol Biol. 370:752-67, 2007), Deinococcus radiodurans (Kim et al., J. Mol. Biol. 361:105-114, 2006), Lactococcus lactis (Stillman et al., Mol Microbiol. 362:106-114, 2006), and Dps from Escherichia coli (Grant et al., Nat Struct. Biol. 5:294–303, 1998). Microbiol. 57: 1101-12, 2005) and Listeria innocua (Ilari et al., Nat Struct. Biol. 7: 38-43, 2000).
[0024] Although the dodecameric nanoparticle structure is very conserved among all Dps, the primary amino acid sequence of Dps varies greatly between different families of bacteria or archaea.
[0025] In some preferred embodiments, the Dps is derived from bacteria, and the Dps derived from bacteria is Dps of Escherichia coli, referred to as EcDps.
[0026] The mature F glycoprotein has three general domains: the extracellular domain (ED), the transmembrane domain (TM), and the cytoplasmic tail (CT). The CT contains a single palmitoylated cysteine residue.
[0027] The F glycoprotein of human RSV is first translated from mRNA into a single 574 amino acid polypeptide precursor (referred to as "F0" or "F0 precursor"), which contains a signal peptide sequence (amino acid 1-25) at the N-terminus. After translation, the signal peptide is removed by a signal peptidase in the endoplasmic reticulum. The remainder of the F0 precursor (i.e., residue 26-574) can be further cut by a cell protease (especially furin) at two polybasic sites (aa109 / 110 and 136 / 137), removing the intervening sequence (amino acid 110-136) of 27 amino acids of pep27 by name and generating a fragment of the connection of F2 (N-terminal part, amino acid 26-109) and F1 (C-terminal part, amino acid 137-574) by name. F1 contains a hydrophobic fusion peptide and two heptad repeat regions (HRA and HRB) at its N-terminus. HRA is close to the fusion peptide, and HRB is close to the TM domain. F1 and F2 fragments are linked together by two natural disulfide bonds. The uncleaved F0 protein or F1-F2 heterodimer without a signal peptide sequence can form RSV F protomers. Three such protomers assemble to form the final RSV F protein complex, which is a homotrimer of three protomers.
[0028] In some embodiments, the F2 domain of the present invention comprises a RSV F protein polypeptide corresponding to amino acids 26-105 of SEQ ID NO:1, and the F1 domain comprises a RSV F protein polypeptide corresponding to amino acids 137-516 of SEQ ID NO:1.
[0029] In some embodiments, the F1 domain truncated fragment contains at least amino acid residues 146-306 corresponding to the wild-type RSV F protein set forth in SEQ ID NO:1, and the F2 domain truncated fragment contains at least amino acid residues 51-104 corresponding to the wild-type RSV F protein set forth in SEQ ID NO:1.
[0030] In some specific embodiments, the F1 domain truncated fragment of the present invention corresponds to amino acid residues 146-306 of the wild-type RSV F protein, and the F2 domain truncated fragment corresponds to amino acid residues 51-104 of the wild-type RSV F protein.
[0031] In some embodiments, the F1 domain truncated fragment and the F2 domain truncated fragment are connected by a linker sequence. Optionally, the linker sequence is GGGSSGS, GGSSG, GGPG, or a 4-10 amino acid sequence consisting of G and S.
[0032] In some embodiments, preferably, the linker sequence is GGPG.
[0033] The recombinant RSV particle antigen provided by the present invention displays the pre-F protein on the surface of dodecamer nanoparticles, and has a higher antigen loading capacity and physical stability than pre-F monomer protein or pre-F trimer protein (for example, pre-F trimer protein with a foldon trimerization structure). Under the same dosage conditions, it is more in line with the economic and efficient principles in actual production.
[0034] In some embodiments, the recombinant head domain further comprises one or more amino acid mutations, wherein the amino acid mutations comprise addition, deletion or substitution of one or more amino acids.
[0035] In some embodiments, the amino acid mutations include non-native disulfide bond addition mutations and cavity filling mutations.
[0036] In some embodiments, the adding non-natural disulfide bond mutation comprises forming artificial intrachain disulfide bonds and / or interchain disulfide bonds by substitution of paired cysteine residues.
[0037] An interchain disulfide bond (SS) generally refers to a bond between sulfur atoms in two different organic molecules.
[0038] An intrachain disulfide bond (SS) refers to the bond between two adjacent sulfur atoms in an organic molecule.
[0039] In the present invention, the disulfide bond connecting two β-folds in a single domain is called an intrachain disulfide bond; the disulfide bond connecting two different domains (for example, connecting an F1 domain and an F2 domain) or connecting two adjacent identical domains (for example, connecting the F1 domains of two adjacent F protein monomers) is called an interchain disulfide bond.
[0040] In some embodiments, the non-natural disulfide bond mutation is selected from at least one group of V164C+K293C, G151C+I288C, H159C+I291C, S55C+L188C, S56C+V187C, S59C+V193C, K75C+E218C, T397C+E487C, S443C+S466C, T323C+I475C, I332C+P480C, S146C+N460C, I148C+Y286C, A149C+Y458C and S150C+Q302C.
[0041] In some embodiments, the non-native disulfide bond mutation is selected from at least one group consisting of S55C+L188C, I148C+Y286C, H159C+I291C, F387C+I492C, and K75C+E218C.
[0042] In some embodiments, the non-native disulfide bond mutations are selected from at least one group consisting of S55C+L188C, I148C+Y286C, and H159C+I291C.
[0043] In some embodiments, preferably, the non-native disulfide bond mutation is a combination of S55C+L188C and I148C+Y286C.
[0044] In some embodiments, preferably, the non-native disulfide bond mutation is a combination of S55C+L188C, I148C+Y286C and H159C+I291C.
[0045] In some embodiments, the cavity-filling mutations include V296F, N67F, L158F, V154L, V154I, V187F, S190V, V192M, L193H, S190F, V207L, K77E, V56I, E60F, E82Y, G139W, K168W, Q202Y, V207F, T219F, V220W, L230F, and V495L.
[0046] In some embodiments, the cavity-filling mutation is selected from at least one of N67F, L158F, V187F, S190V, V296F, V192M, V495L, S190F and E82Y.
[0047] In some embodiments, the cavity-filling mutation is selected from at least one of N67F, S190V, V296F, and V495L.
[0048] In some embodiments, the cavity-filling mutations are selected from at least two of N67F, S190V, and V296F.
[0049] In some embodiments, preferably, the cavity-filling mutation is a combination of N67F and S190V.
[0050] In some embodiments, preferably, the cavity-filling mutation is a combination of N67F, S190V and V296F.
[0051] In the particle antigen amino acid sequence of the present invention, in particular the recombinant head domain also includes 1 to 4 naturally occurring substitutions (P102A, I379V, M447V and E218A) relative to the wild-type RSV F protein sequence.
[0052] In some embodiments, the naturally occurring substitution is selected from at least one of P102A, I379V, M447V, and E218A.
[0053] In some embodiments, the naturally occurring substitution is P102A.
[0054] In some embodiments, the amino acid mutation may further include an electrostatic mutation that reduces the ionic repulsion between residues that are close to each other in the folded structure of the protein or increases the ionic attraction between the residues.
[0055] In some embodiments, the electrostatic mutations include K80E, E92D, G184N, V185N, K201Q, K209Q, and S35F.
[0056] In some embodiments, preferably, the electrostatic mutation is G184N.
[0057] In some specific embodiments, the amino acid sequence of the recombinant respiratory syncytial virus particle antigen provided by the present invention is shown in SEQ ID NO:5.
[0058] In some specific embodiments, the amino acid sequence of the recombinant respiratory syncytial virus particle antigen provided by the present invention is shown in SEQ ID NO:6.
[0059] In some specific embodiments, the amino acid sequence of the recombinant respiratory syncytial virus particle antigen provided by the present invention is shown in SEQ ID NO:7.
[0060] In some specific embodiments, the amino acid sequence of the recombinant respiratory syncytial virus particle antigen provided by the present invention is shown in SEQ ID NO:8.
[0061] The particle antigen disclosed in the present invention comprises a signal peptide sequence required for expression or a linker sequence connected to a purification tag, and these signal peptide sequences or linker sequences connected to a purification tag can be removed in the final product.
[0062] In some embodiments, the particulate antigen comprises a signal peptide required for expression, which is a heterologous signal peptide.
[0063] In some embodiments, the heterologous signal peptide is an IgG signal peptide with an amino acid sequence of MGWSCIILFLVATATGVHS.
[0064] In some embodiments, the particle antigen also introduces affinity tags for subsequent purification during vector construction, such as strep tag (amino acid sequence: WSHPQFEK), Monoclonal Flag-Tag (amino acid sequence: DYKDDDDK) and His tag (amino acid sequence: HHHHHHHH). These tag sequences can be removed in the final product.
[0065] The particle antigen of the present invention displays the F protein polypeptide in the pre-fusion conformation on the surface of the dodecamer nanoparticle.
[0066] The present invention also provides the use of the particle antigen in preparing a vaccine for preventing RSV infection.
[0067] The present invention also provides a vaccine for preventing RSV infection, comprising the above-mentioned particle antigen, and the vaccine provides protection against infection by at least one of RSV A subtype and / or B subtype.
[0068] The present invention discloses a vaccine for preventing RSV infection, further comprising an immune adjuvant, wherein the immune adjuvant comprises at least one of aluminum adjuvant, squalene, tocopherol, MPL, LPA, CpG, poly(I:C) and QS-21.
[0069] In some embodiments, the immune adjuvant is a liposome adjuvant, the ingredients of which include MPL, QS-21, DOPC and cholesterol.
[0070] The present invention also provides a method for preparing the particle antigen, comprising the following steps:
[0071] S1, synthesizing the DNA sequence corresponding to the particle antigen and cloning it into a plasmid vector;
[0072] S2, transfecting host cells with the recombinant plasmid vector and expressing the recombinant plasmid vector, wherein the host cells are eukaryotic cells;
[0073] S3. Purify the culture product to obtain the particulate antigen.
[0074] In some embodiments, the vaccine of the present invention generally also includes a pharmaceutically acceptable carrier and / or excipient such as a buffer. Pharmaceutically acceptable carriers and excipients are well known and can be selected by those skilled in the art. Optionally, a pharmaceutically acceptable carrier or excipient also contains at least one component that stabilizes solubility and / or stability. Examples of solubilizers / stabilizers include detergents, such as laurel sarcosine and / or tween. Other examples of solubilizers / stabilizers include arginine, sucrose, trehalose, etc. Therefore, those skilled in the art can select suitable excipients and carriers to produce formulations suitable for administration to a subject by a selected route of use. Suitable excipients include, but are not limited to, glycerol, polyethylene glycol, KCl, calcium ions, magnesium ions, manganese ions, zinc ions, and other divalent cation-related salts, etc.
[0075] Generally, an adjuvant should be selected to enhance a Th1 biased immune response in a subject or subject population to which the vaccine is administered and to be safe and effective in the subject or subject population.
[0076] The present invention also provides a method for preparing the above-mentioned vaccine for preventing RSV infection, which comprises:
[0077] S1, culturing mammalian host cells to express the particle antigen;
[0078] S2, purifying the particulate antigen expressed in step (1);
[0079] S3. Mix the purified particulate antigen and immune adjuvant in proportion.
[0080] In some embodiments, additional steps such as gene synthesis, construction of expression vectors, and freeze-drying of purified proteins are also included. The expressed fusion polypeptide can be recovered and purified from the recombinant cell culture by any one or more of many methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion / cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. Finally, high performance liquid chromatography HPLC can be used in the final purification step.
[0081] Compared with the prior art, the present invention has the following beneficial effects:
[0082] The present invention obtains a particle antigen capable of displaying the RSV F protein with specific epitopes for the pre-fusion conformation protein on the surface of dodecamer nanoparticles by targeted truncation, reconstruction, stabilization modification and particle formation of the wild-type RSV F protein. This ensures that the RSV F protein can induce effective neutralizing antibody responses and binding antibody responses to respiratory syncytial virus while maintaining the stable pre-fusion conformation and protein loading of the F protein, and has excellent immunoreactivity or immunogenicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0083] The following drawings are intended only to illustrate and explain the present invention, and are not intended to limit the scope of the present invention.
[0084] Figure 1 : SDS-PAGE electrophoresis results of the F142 protein in Example 10 of the present invention stored at 4°C and after one freeze-thaw cycle;
[0085] Figure 2 : SDS-PAGE electrophoresis results of the F144 protein in Example 10 of the present invention stored at 4°C and after one freeze-thaw cycle;
[0086] Figure 3 : SEC-HPLC results of the F142 protein in Example 10 of the present invention after being stored at 4°C and subjected to one freeze-thaw cycle, the black line indicates storage at 4°C, and the blue line indicates one freeze-thaw cycle;
[0087] Figure 4: SEC-HPLC results of the F144 protein in Example 10 of the present invention after being stored at 4°C and subjected to one freeze-thaw cycle, the black line indicates storage at 4°C, and the blue line indicates one freeze-thaw cycle;
[0088] Figure 5 : The Pre-F specific IgG content in the serum of mice immunized 3 weeks after in Example 11 of the present invention;
[0089] Figure 6 : The Pre-F specific IgG content in the serum of mice immunized 5 weeks after the present invention in Example 11;
[0090] Figure 7 : The neutralizing antibody titer ND in the serum of mice immunized 3 weeks after Example 11 of the present invention 50 ;
[0091] Figure 8 : The neutralizing antibody titer ND in the serum of mice immunized for 5 weeks in Example 11 of the present invention 50 ;
[0092] Fig. 9 : Schematic diagram of the linear structure of wild-type RSV F protein;
[0093] Fig.10 : Schematic diagram of the linear structure of the recombinant respiratory syncytial virus particle antigen of the present invention;
[0094] Fig.11 : Schematic diagram of the design principle that non-native disulfide bond mutations in the exemplary combined mutant antigen design of Example 7 of the present invention are beneficial to stabilizing the PreF conformation. DETAILED DESCRIPTION
[0095] The present invention will be further described below by non-limiting examples, and it is well known to those skilled in the art that many modifications may be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following examples are only intended to illustrate the present invention and should not be considered to limit the scope of the present invention, because the embodiments are necessarily diverse. The terms used in this specification are only intended to illustrate specific embodiments, and not as a limitation, and the scope of the present invention is defined in the appended claims.
[0096] Unless otherwise specified, all technical and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which this invention belongs. The preferred methods and materials of the present invention are described below, but any methods and materials similar or equivalent to those described in this specification can be used to implement or test the present invention. The following experimental methods are conventional methods or methods described in product specifications unless otherwise specified, and the experimental materials used can be easily obtained from commercial companies unless otherwise specified.
[0097] Definition of terms
[0098] In the present application, the term "F0 polypeptide" (F0) refers to the precursor polypeptide of RSV F protein, which consists of a signal polypeptide sequence, an F1 polypeptide sequence, a pep27 polypeptide sequence, and an F2 polypeptide sequence. With few exceptions, the F0 polypeptide of a known RSV strain consists of 574 amino acids.
[0099] In the present application, the term "F1 polypeptide", "F1 domain" (F1) refers to the polypeptide chain of mature RSV F protein. Natural F1 includes the approximate residue 137-574 of RSV F0 precursor and is composed of (from N-terminal to C-terminal) extracellular region (approximate residue 137-524), transmembrane domain (approximate residue 525-550) and cytoplasmic domain (approximate residue 551-574). As used herein, the term encompasses both natural F1 polypeptides and F1 polypeptides including modifications (e.g., amino acid substitutions, insertions or deletions) from native sequences, which are, for example, designed to stabilize F mutants or enhance the immunogenicity of F mutants.
[0100] In the present application, the term "F2 polypeptide", "F2 domain" (F2) refers to the polypeptide chain of mature RSV F protein. Natural F2 includes the approximate residues 26-109 of the RSV F0 precursor. As used herein, the term encompasses both natural F2 polypeptides and F2 polypeptides from native sequences including modifications (e.g., amino acid substitutions, insertions or deletions), which are designed, for example, to stabilize F mutants or enhance the immunogenicity of F mutants. In natural RSV F protein, the F2 polypeptide is connected to the F1 polypeptide by two disulfide bonds to form a F2-F1 heterodimer.
[0101] In the present application, the term "native" or "wild-type" protein, sequence or polypeptide refers to a naturally occurring protein, sequence or polypeptide that has not been artificially modified by selective mutation.
[0102] In this application, the term "pep27 polypeptide" or "pep27" refers to a 27 amino acid polypeptide that is cleaved from the F0 precursor during RSV F protein maturation. The sequence of pep27 is flanked by two furin cleavage sites that are cleaved by cellular proteases during F protein maturation to generate F1 and F2 polypeptides.
[0103] In the present application, the term "DS-Cav1" refers to a form of RSV F protein having the amino acid sequence described in McLellan et al., Science, 342(6158), 592-598, 2013, which has stability and immunogenicity superior to wild-type (WT) RSV F protein and post-fusion F protein (post-F). The specific amino acid sequence used in the present application is shown in SEQ ID NO: 4.
[0104] In the present application, foldon or foldon domain generally refers to the residues at the C-terminus of phage T4 fiber protein. In the present application, the foldon domain can be the 27 residues at the C-terminus of phage T4 fiber protein or a mutant thereof. An example is an amino acid sequence having GYIPEAPRDGQAYVRKDGEWVLLSTFL. In the present application, the foldon domain can be a truncation or an extension obtained by truncating the 27 residues at the C-terminus of phage T4 fiber protein or increasing 1, 2, 3, 4, 5, 6 or 10 amino acids at the N-terminus or C-terminus. The mutant mentioned here generally refers to a sequence that is different from a reference sequence because it contains one or more differences (mutations). The difference can be a substitution, deletion or insertion of one or more amino acids.
[0105] In the present application, pXCS847 refers to the RSV F protein mutant designed with reference to Pfizer CN108738312A, which has major amino acid mutations T103C; I148C; S190I; D486S. The specific amino acid sequence used in the present application is shown in SEQ ID NO:10.
[0106] In the present application, PreF-1345 refers to a form of RSV F protein designed with reference to CN115103682A of Moderna, which has major amino acid mutations S155C; S290C; A149C; Y458C; S190F; V207L. The specific amino acid sequence used in the present application is shown in SEQ ID NO:11.
[0107] In the present application, PreF-NP refers to the RSV F particle protein form designed with reference to CN112512567A of Sanofi, which has major amino acid mutations E328N, S348N, R507N, K498L, and I217P on the F polypeptide. The specific amino acid sequence used in the present application is shown in SEQ ID NO:12.
[0108] In the present application, the term "D25" refers to the antibody described in CN101778866B, which has the amino acid sequence of heavy chain CDR1: NYIIN, heavy chain CDR2: GIIPVLGTVHYAPKFQG, heavy chain CDR3: ETALVVSTTYLPHYFDN and light chain CDR1: QASQDIVNYLN, light chain CDR2: VASNLET, light chain CDR3: QQYDNLP.
[0109] In the present application, the term "101F" refers to the antibody described in US20060159695A1, which has the amino acid sequence of heavy chain CDR1: TSGMGVS, heavy chain CDR2: HIYWDDDKRYNPSLKS, heavy chain CDR3: LYGFTYGFAY and light chain CDR1: RASQSVDYNGISYMH, light chain CDR2: AASNPES, light chain CDR3: QQIIEDPWT.
[0110] In the present application, the term "Mota" or "motavizumab" refers to the antibody described in WO2007002543A2, which has the amino acid sequence of heavy chain CDR1: TSGMSVG, heavy chain CDR2: DIWWDDKKDYNPSLKS, heavy chain CDR3: SMITNWYFDV and light chain CDR1: SASSRVGYMH, light chain CDR2: DTSKLAS, light chain CDR3: FQGSGYPFT.
[0111] In the present application, the term "AM14" refers to the antibody described in WO2008147196A2, whose VH region (VDJ segment) has the amino acid sequence EVQLVESGGGVVQPGRSLRLSCAASGFSFSHYAMHWVRQAPGKGLEWVAVI SYDGENTYYADSVKGRFSISRDNSKNTVSLQMNSLRPEDTALYYCARDRIVDDYYYYGMDVWGQGATVTVSS, and the VL region (VJ segment) has the amino acid sequence DIQMTQSPSSLSAVGDRVTITCQASQDIKKYLNWYHQKPGKVPELLMHDASN LETGVPSRFSGTDFTLTISSLQPEDIGTYYCQQYDNLPPLTFGGGTKVEIKRTV.
[0112] Example 1. Screening of single mutation information
[0113] Each mutant of the present embodiment is designed and prepared based on the wild-type (abbreviated as WT) RSV F protein amino acid sequence described in SEQ ID NO:1. The design of various F protein single mutants is described as follows, and the F protein single mutant is provided in the form of a trimer, including a foldon domain and an amino acid mutation introduced, such as adding a non-natural disulfide bond mutation, a cavity filling mutation, and an electrostatic mutation. These F protein single mutants include an IgG signal peptide (MGWSCIILFLVATATGVHS) and two separate polypeptide chains. One of the polypeptide chains, the F2 polypeptide includes the amino acid 26-106 of SEQ ID NO:1, except the mutation introduced as described. Another polypeptide chain includes the F1 polypeptide (residues 136-513) connected to the N-terminal of the foldon domain, except the mutation introduced as described, and their general introduced modifications also include del_P27 replaced by ARGSGSG, R106Q and F137S. It also contains a purification tag His-Tag (HHHHHHHH), an affinity tag Monoclonal Flag-Tag (DYKDDDDK) and a linker sequence (eg GSGSG). The signal peptide (residues 1-25) and pep27 (residues 110-136) of SEQ ID NO: 1 are cleaved from the F0 precursor during the expression process.
[0114] The amino acid sequences of each RSV F protein mutant and control group protein were designed according to the table below. The amino acid sequence was codon optimized according to the host CHO cells to determine the nucleic acid sequence and perform gene synthesis.
[0115] Table 1. Mutants containing only added non-native disulfide bonds
[0116]
[0117]
[0118] Table 2. Mutants containing only cavity-filling mutations
[0119]
[0120]
[0121] Table 3. Mutants containing only electrostatic mutations
[0122] Plasmid name mutation pCHO3.1-F91 K80E pCHO3.1-F92 E92D pCHO3.1-F94 G184N pCHO3.1-F95 V185N pCHO3.1-F96 K201Q pCHO3.1-F97 K209Q pCHO3.1-F98 K421N pCHO3.1-F99 N426S pCHO3.1-F100 K465E pCHO3.1-F101 E487N pCHO3.1-F102 D489N pCHO3.1-F103 K508E pCHO3.1-F104 S35F
[0123] The plasmid transformation, preparation and enzyme digestion identification were carried out according to the method of Example 3. The concentration was measured after plasmid amplification. Each plasmid could obtain a high amplification concentration. All plasmids were sequenced and identified to have the correct target gene sequence. The recombinant plasmid vector carrying the target gene has been successfully transferred into the host cell and has been successfully amplified.
[0124] Referring to the method of Example 4, the obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture.
[0125] Use PBS to dilute the coated antibody D25 or the coated antibody motavizumab (referred to as mota) to 5ng / μL, add 200μL to each well of the 96-well plate, and incubate overnight at 4℃. Wash once with PBST. Block the ELISA detection plate with 250μL 2% BSA / PBS, block for 1 hour at room temperature, and wash once with PBST. Add 200μL protein supernatant to each well and incubate at room temperature for 1h. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the appropriate dilution (D25-1:8000, mota-1:16000) in 0.2% BSA / PBS, add 200μL to each well, and incubate at room temperature for 1 hour. Wash 4 times with PBST. Add 100μL substrate solution (TMB two-component solution A:B=1:1 mixture), react at room temperature for 15-20min, add 100μL stop solution, read the OD value, and calculate the sample concentration according to the regression analysis equation. The percentage of PreF conformation of the protein after being placed at 4°C for 7 days was calculated and expressed as the ratio of the active concentrations of D25 and Mota.
[0126] Table 4. PreF conformation ratio of F protein single mutants after 7 days at 4°C
[0127]
[0128] After the protein supernatant was placed at 4°C for 7 days, compared with the DS-Cav1 control group, the F protein single mutants F24, F27, F30, F31, F32, F35, F38, F40, F41, F46, F53 and F123 containing only added non-native disulfide bond mutations, and the F protein single mutants F58, F76, F79, F80, F81, F84, F85 and F107 containing only cavity filling mutations still had a higher proportion of PreF conformation. Therefore, in the design of F protein single mutants, the cavity-filling mutations N67F, L158F, V187F, S190V, V192M, V495L, S190F and E82Y, as well as the added non-native disulfide bond mutations V164C+K293C, G151C+I288C, S55C+L188C, S56C+V187C, S59C+V193C, T397C+E487C, S443C+S466C, T323C+I475C, I332C+P480C, S146C+N460C, A149C+Y458C and S150C+Q302C, these single mutation designs made important contributions to the stabilization of PreF conformation and were superior to DS-Cav1. However, the single F protein mutants F91-F104 containing only electrostatic mutations cannot achieve a good effect of stabilizing the PreF conformation during long-term storage at 4°C by relying solely on this mutation method, and should be considered for application in the subsequent combined mutation design for synergistic enhancement.
[0129] Example 2. Construction of particle antigen plasmid and gene synthesis
[0130] Although the mutants with single mutations in the above examples are superior to DS-Cav1 in terms of stability, from a practical point of view, the presence of antigenic epitopes siteI and siteIV in the stalk region of the extracellular domain of the preF protein will compete with the quaternary epitopes siteΦ and siteV that only exist in the pre-fusion conformation of the RSV F protein, which will reduce the quality of the antibody response to a certain extent. For example, in previous studies, we found that proteins in the form of trimers or particles based on the extracellular domain of the F protein supplemented with stabilizing amino acid modifications can also be used as immunogens to produce neutralizing antibodies in mice, but the antigenic epitopes siteI and siteIV in the stalk region produce obvious antigenic competition with the antigenic epitopes siteΦ and siteV in the head region.
[0131] To solve this problem, this embodiment focuses more on the structural modification of the F protein, especially on fully exposing the quaternary epitopes siteΦ and siteⅤ that only exist in the pre-fusion conformation of the RSV F protein, as well as the head domain of siteⅡ located in the middle of pre-F, and further provides a recombinant respiratory syncytial virus particle antigen.
[0132] The amino acid sequences of the granule protein and the control group were designed according to the following table. The amino acid sequence was codon optimized according to the host CHO cells to determine the nucleic acid sequence for gene synthesis.
[0133] Table 5. Construct amino acid sequence design
[0134]
[0135]
[0136] The F-head involved in this embodiment has a truncated F1-F2 structure, and the F-head' has a truncated F2-F1 structure.
[0137] Example 3. Plasmid transformation, preparation and enzyme digestion identification
[0138] The synthesized target gene was inserted into the eukaryotic plasmid pCHO3.1 vector for transfection and expression. Each constructed recombinant plasmid was transformed into E. coli DH5α competent cells, and the glycerol bacteria into which the plasmid containing the target gene was transferred was transferred to 150mL LB liquid medium (final Amp concentration was 100μg / ml), and cultured overnight in a shaking incubator at 37°C and 2000rpm. The plasmid was extracted using an endotoxin-free plasmid extraction kit, and the plasmid concentration of the extract was measured and enzyme digestion was performed for identification. The specific reaction system is shown in the following table.
[0139] Table 6. Enzyme digestion reaction system
[0140]
[0141] After plasmid amplification, the concentration was measured. Each plasmid was able to obtain a relatively high amplification concentration. Several exemplary plasmid concentration measurement results are shown in the following table.
[0142] Table 7. Plasmid concentration determination results
[0143] Plasmids Concentration (μg / ml) Total amount (μg) pCHO3.1-EcDps-F head 716 1.0 pCHO3.1-EcDps 804 1.2 pCHO3.1-DS-Cav1 935 1.4
[0144] The results of enzyme digestion were detected by 1% agarose gel electrophoresis, and clear bands were visible at the corresponding size. All plasmids were sequenced and identified to have completely correct target gene sequences. The recombinant plasmid vector containing the target gene has been successfully transferred into the host cell and has been successfully amplified.
[0145] Example 4. Protein expression
[0146] The obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture.
[0147] ExpiCHO-S cells (Thermo) were cultured in EmCD CHO-S203 (Eminence / L20301) medium supplemented with 6 mM L-glutamine (sigma / G5146). One day in advance, 0.25E5 cells / well were plated in a 96-well plate (supplemented with 10% FBS) and cultured in a 37°C, 8% CO2 incubator. On the day of transfection, the 96-well plate with cells was replaced with fresh EmCD CHO-S203 medium containing L-glutamine. The transfection incubation system was prepared with EmCD CHO-S203 medium containing L-glutamine (volume was 50% of the transfection volume), wherein the DNA dosage was 1 μg / ml, and the ratio of transfection reagent PEI (Polysciences / 24765-1) to DNA was 3. PEI and DNA were mixed and incubated for 5 minutes and then added to a 96-well plate with cells. The culture was incubated in an incubator at 37°C and 8% CO2. After 24 hours of transfection, the temperature was lowered to 32°C for culture, and Advanced Feed1 (sigma / 24368-1L) was added as feed at a volume ratio of 5%. The culture was stopped on the 7th day after transfection and the supernatant was collected.
[0148] Example 5. Evaluation of the immunoreactivity of particle antigens
[0149] This example specifically examines the immunoreactivity of the particle antigen, and whether the particle domain EcDps in the particle antigen interferes with the binding of D25 monoclonal antibody and Mota monoclonal antibody to the neutralizing antibody epitopes Siteφ and SiteⅡ. Specifically, the constructed and expressed EcDps-F head and EcDps are used as exemplary investigation objects, and the coated antibody D25 or the coated antibody motavizumab (referred to as mota) is diluted with PBS to 5 ng / μL, and 200 μL is added to each well and incubated at 4°C overnight. Wash once with PBST. Block the ELISA test plate with 250 μL 2% BSA / PBS, block at room temperature for 1 hour, and wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the adapted dilution (D25-1:8000, mota-1:16000) in 0.2% BSA / PBS, add 200 μL to each well, and incubate at room temperature for 1 hour. Wash 4 times with PBST.
[0150] Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1 mixture), react at room temperature for 15-20 min, add 100 μL of stop solution, and read the OD value.
[0151] The results are shown in the following table. The EcDps-F head of the present invention has better immunoreactivity than DS-Cav1, and it can be found that the F head part with PreF specific epitopes Siteφ and SiteⅡ binds to the specific monoclonal antibody D25 and mota, while the particle domain EcDps does not have the ability to specifically bind to D25 or mota, and basically does not interfere with the detection results.
[0152] Table 8. Binding of target proteins to D25 and Mota
[0153]
[0154] Example 6. Evaluation of thermal stability of particle antigens
[0155] The protein expression supernatant was taken and incubated at 50℃ and 70℃ for 1 hour respectively. Then, the double antibody sandwich ELISA method was used, with 101F as the coating antibody, D25 and motavizumab (hereinafter referred to as Mota) as the labeled antibody detection pair, to detect the protein activity, PreF conformation ratio and thermal stability of the particle antigen under different extreme temperature conditions. Among them, the protein activity was expressed by the activity concentration of the epitope-specific neutralizing antibody detection, the PreF conformation ratio was expressed by the ratio of the activity concentration of D25 to Mota, and the conformational thermal stability was expressed by the ratio of the activity concentration of D25 at 50℃-1h or 70℃-1h to that at low temperature. The exemplary particle antigen EcDps-F head was used as the object of investigation, and F head-foldon, F head'-foldon and DS-Cav1 were used as controls.
[0156] The results showed that at 50℃, the protein activity did not change significantly, and the PreF protein conformation was highly stable. Under the more extreme temperature of 70℃, the protein activity and Pre-F conformational stability of the particle antigen EcDps-F head, F head-foldon, F head'-foldon and DS-Cav1 control proteins were greatly affected, so high temperature was not conducive to the stability of the Pre-F conformation. However, for the particle antigen EcDps-F head without any stabilization modification, its stability decrease at 50℃ and 70℃ was smaller than that of the DS-Cav1 control protein in the form of trimer, and was significantly better than F head-foldon and F head'-foldon provided in the form of trimer without any stabilization modification. Even under such extreme conditions, the activity of the particle antigen EcDps-F head was still much higher than that of the F head-foldon, F head'-foldon and DS-Cav1 control proteins. Although the proportion of the PreF conformation of the particle antigen EcDps-F head at 70℃ was lower than that of the control protein, the protein activity far higher than that of the control was sufficient to make up for this defect in actual production. Therefore, unlike the DS-Cav1 control protein which itself has multiple stabilizing modifications (having double cysteine mutations S155C and S290C, cavity filling mutations S190F and V207L, and a foldon trimerization domain) and the F head-foldon and F head'-foldon which have similar structures but are provided in the form of trimers, the particle antigen composed of the reconstructed F head and particle domain EcDps of the present invention still has significantly better protein activity, PreF conformation protein content and thermal stability than F head-foldon, F head'-foldon and DS-Cav1 without any amino acid modification, which confirms the importance of structural modification and granulation domain in improving thermal stability.
[0157] Table 9. Protein activity and PreF conformation ratio at 70℃
[0158]
[0159] Table 10. Conformational stability
[0160]
[0161] In summary, after immunoreactivity evaluation and thermal stability evaluation, the particle antigen EcDps-Fhead of the present invention still has significantly better immunoreactivity, protein activity, PreF conformation protein content and thermal stability than the DS-Cav1 control protein even without any amino acid modification, and all aspects of the properties are also better than the F head-foldon and F head'-foldon, which are also without any amino acid modification, have similar structures but are provided in the form of trimers.
[0162] Those skilled in the art understand that antigens can be divided into proteins, lipoproteins, lipopolysaccharides, polysaccharides, glycoproteins, polypeptides, nucleic acids and other antigens according to their chemical composition, among which bacteria, viruses, animal sera and the like are complete antigens, which have both immunogenicity and immunoreactivity; while small molecule compounds such as certain drugs, oligosaccharides, nucleotides and the like are haptens, which only have immunoreactivity but not immunogenicity. The particle antigen EcDps-F head provided by the present invention is a complete antigen, and while verifying its good immunoreactivity, it can be undoubtedly determined that it must have immunogenicity, can stimulate immune cells to activate, proliferate and differentiate, and finally produce antibodies to induce an immune response, and can be used as a potential candidate antigen for the preparation of a vaccine to prevent RSV infection, providing protection against at least one infection of RSV subtype A and / or subtype B.
[0163] Example 7. Exemplary Combinatorial Mutant Particle Antigen Design
[0164] In the above research, the inventors have provided a particle antigen EcDps-Fhead that can be used as a candidate vaccine and has significantly better functions than DS-Cav1 in all aspects without relying on any stabilizing amino acid modifications in the F protein.
[0165] In addition, in the scheme of this embodiment, the inventors also introduced a series of combined amino acid mutations in the F head part based on the specially designed particle antigen EcDps-Fhead, and the combined amino acid mutation design was basically made based on the scheme of screening the individual mutation information in Example 1 of the present invention. Specifically, they are cavity filling mutations N67F, L158F, V187F, S190V, V192M, S190F and E82Y, non-natural disulfide bond mutations V164C+K293C, G151C+I288C, S55C+L188C, S56C+V187C, S59C+V193C and S150C+Q302C, and electrostatic mutations K80E, E92D, G184N, V185N, K201Q, K209Q and S35F.
[0166] During the screening, the inventor unexpectedly found that although some combined mutant particle antigens introduced mutations that were screened by individual mutations to maintain the stability of the Pre-F conformation during long-term storage at 4°C, they performed poorly in maintaining protein activity or thermal stability of the Pre-F conformation under high temperature conditions of 60°C. Therefore, in the other designs of combined mutant particle antigens, the schemes that were poor in individual mutation screening were not completely abandoned, and the inventors found in the experiment that some schemes that did not perform well in individual mutation screening could play an unexpected effect in combined mutations. The following table lists exemplary particle antigens with combined mutations and control group particle proteins. The N-terminal signal peptide of the combined mutant particle antigen is an IgG signal peptide, and its amino acid sequence is MGWSCIILFLVATATGVHS, and the granulation domain connected thereto is EcDps, and the C-terminus is the RSV F head introduced with combined mutations. Among them, the structure of the RSV F head is, from the N-terminus to the C-terminus, a truncated fragment of the F1 domain (residues 146-306), a linker sequence, and a truncated fragment of the F2 domain (residues 51-104). In addition, an affinity tag for easy purification was added when designing the combined mutant particle antigen. In addition, the inventors also designed two control particle antigens DS-Cav1-N and DS-Cav1-N' based on DS-Cav1, in which DS-Cav1-N' and the combined mutant particle antigen of the present invention adopt the same structural design (i.e., EcDps-F head), and only the amino acid mutation information is different (S190F, V207L, S155C+S290C). All amino acid sequences are codon-optimized according to the host CHO cells to determine the nucleic acid sequence for gene synthesis, and the target protein is expressed through the CHO expression system after plasmid transformation, preparation and enzyme digestion identification.
[0167] Table 11. Combination mutant particle antigen design
[0168]
[0169] Example 8. Evaluation of protein activity, conformational proportion and conformational thermal stability in the supernatant of combined mutant particle antigens
[0170] After three days of expression of the combined mutant granule protein, the expressed cell supernatant was collected by centrifugation at 10,000 rpm, and the expression supernatant was taken separately and incubated at 60°C and 70°C for 1 hour respectively. Then, the double antibody sandwich ELISA method was used, with 101F as the coating antibody, D25, motavizumab (hereinafter referred to as Mota) or AM14 as the labeled antibody detection pair, to detect the protein activity of each combined mutant granule protein expressed, the proportion of different structures after incubation at different temperatures, and the thermal stability of the PreF conformation. Among them, the protein activity is expressed by the activity concentration of the epitope-specific neutralizing antibody detection, the proportion of different structures is expressed by the ratio of the activity concentration of D25 or AM14 to Mota at 0d, and the conformational thermal stability is expressed by the ratio of the activity concentration of D25 at 60°C-1h / 0d and 70°C-1h / 0d. The results are shown in the following table.
[0171] Table 12. Protein activity in the supernatant after incubation at different temperatures
[0172]
[0173]
[0174] Note: “ / ” indicates no reactivity detected or not determined
[0175] Table 13. Structural proportion and conformational thermal stability
[0176]
[0177] In terms of protein activity, the combined mutant granule protein group and the DS-Cav1-N and DS-Cav1-N' control group granule proteins can be expressed normally, and the protein activities of F141, F142, F143 and F144 under different temperature conditions are much higher than those of the DS-Cav1-N and DS-Cav1-N' control groups, and are less affected by high temperatures, while having good immunoreactivity. In terms of the proportion of different structures, compared with the control group, the D25 / Mota ratios (0d) of F141 to F144 are higher, indicating that the F protein displayed on the surface of the granule aggregate provided by the present invention is in a pre-fusion conformation. And the AM14 / Mota ratios of each combined mutant granule protein are all low, which further confirms that the present invention has successfully constructed a granule antigen rather than a trimeric protein antigen.
[0178] In terms of thermal stability, the 60℃-1h / 0d D25 concentration ratios measured by all combined mutant granule proteins were comparable to the level of control group proteins, with no statistical difference. After extreme high temperature treatment at 70℃, the 70℃-1h / 0d D25 concentration ratios measured by all granule proteins were higher than those of the control group proteins. Therefore, the granule antigens of the present invention have better thermal stability under extreme temperature conditions. This excellent thermal stability is due to the special EcDps-F head (F1-F2) structural design of the present invention on the one hand, and the important contribution made by the amino acid combination mutation on the other hand.
[0179] Example 9. Effect of temperature on protein properties
[0180] This example uses F142 and F144 in the combined mutant particle antigen as exemplary representatives to study the effect of temperature on protein properties. After the large-scale preparation of F142 and F144 proteins was purified using a two-step purification method of nickel column affinity chromatography and molecular sieve chromatography, the protein concentration was diluted to a detection concentration of 4ng / ml, and then the Pre-F pre-fusion conformation-specific monoclonal antibody D25 was used to identify the pre-fusion conformation stability of the purified protein. The conformational thermal stability was expressed as the D25 activity concentration ratio of 60℃-1h / 4℃, and the storage stability under 4℃ was expressed as the D25 activity concentration ratio of 4℃-7d / 4℃. The results are shown in the following table.
[0181] Table 14. Protein purification yield
[0182] protein Yield after purification (mg / L) Purity (SDS-PAGE, R) F142 10.7 >90% F144 24.5 >90%
[0183] Table 15. Characterization of protein conformational thermal stability and storage stability
[0184]
[0185] Table 16. Characterization of protein conformational thermal stability and storage stability continued
[0186]
[0187] The combined mutant particle antigen protein disclosed in the present invention has high expression and purification yield. In terms of stability, the stability of the F protein in the pre-fusion conformation decreases after incubation at 60°C for 1 hour or storage at 4°C for 7 days compared to before treatment, but the decrease is less than 50% under such extreme conditions, which is relatively stable. However, the inventors found that the combined mutant particle antigen does not seem to be suitable for long-term storage at 4°C in the form of a vaccine semi-finished product or finished product. Therefore, in order to optimize the antigen storage conditions, the inventors also tried a -80°C frozen storage method.
[0188] Example 10. Effect of freeze-thaw on protein properties
[0189] This example continues to use F142 and F144 as exemplary representatives of combined mutant particle antigens to study the effect of freezing and thawing once on protein properties. Take out the protein sample frozen at -80°C and place it on ice or in a low-temperature environment at 4°C, slowly add an appropriate amount of protein dissolution buffer, and gently stir the sample at the same time, and continue to stir the sample at low temperature until the protein is completely dissolved. In order to explore whether freezing and thawing once will change the properties of the protein, it is characterized from multiple aspects such as protein degradation, particle size change, conformational change, and protein molecular weight.
[0190] 10.1SDS-PAGE:
[0191] The F142 and F144 proteins stored at 4°C and frozen and thawed once were used as test samples and subjected to SDS-PAGE electrophoresis. The results were as follows: Figure 1 and Figure 2 As shown, the protein bands after one freeze-thaw cycle are consistent with the protein stored at 4°C, but the protein stored at 4°C has slightly more degradation bands, and the protein stored at -80°C is better.
[0192] 10.2DLS particle size detection:
[0193] DLS (Dynamic Light Scattering) detection showed that there was no significant difference in the particle size changes of F142 and F144 proteins before and after freezing and thawing, and the particle size was about 22 nm, which was in line with expectations.
[0194] 10.3 ELISA conformational changes:
[0195] The double antibody sandwich ELISA method was used, with 101F as the coating antibody and D25 as the labeled antibody detection pair, to detect the activity concentration of F142 and F144 proteins stored at 4°C and after one freeze-thaw. The results are shown in the following table. The ratio of the D25 conformation concentration detected after one freeze-thaw and 4°C storage is close to 1, so one freeze-thaw has no effect on the protein conformation.
[0196] Table 17. Conformational changes before and after freeze-thaw
[0197]
[0198] 10.4SEC-HPLC:
[0199] The molecular weights of F142 and F144 proteins stored at 4°C and frozen and thawed once were determined by SEC-HPLC. Figure 3 and Figure 4 As shown in the figure, the peak positions of the protein are consistent before and after freezing and thawing, and freezing and thawing once has almost no effect on the protein size and purity.
[0200] Example 11. Immunological evaluation of exemplary combined mutant particle antigens
[0201] Female BALB / C mice aged 6-8 weeks were selected for immunization and randomly divided into groups of 6 mice each. The mice were double-point immunized with the vaccine by intramuscular injection on days 0 and 21, 50 μL each in the left and right legs. The immunogens included exemplary candidate antigens F142 and F144; WT (SEQ ID NO: 1), DS-Cav1 (SEQ ID NO: 4), pXCS847 (SEQ ID NO: 10), PreF-1345 (SEQID NO: 11) and PreF-NP (SEQ ID NO: 12) positive control groups; and PBS negative control group. The dose of immunogen was 12 μg / mouse, and the dose of liposome adjuvant (hereinafter referred to as adjuvant) was 1 / 20 HD per mouse (1 HD adjuvant is 0.5 ml, containing 50 μg MPL, 50 μg QS-21, 1 mg DOPC, 0.25 mg cholesterol, 4.835 mg sodium chloride, 0.15 mg anhydrous disodium hydrogen phosphate, 0.54 mg potassium dihydrogen phosphate and water for injection). Serum was collected on the 20th day and the 35th day, respectively, and the collected serum was stored at -20°C for subsequent neutralizing antibody and binding antibody detection.
[0202] 11.1 Binding antibody detection:
[0203] (1) Dilute the serum sample to be tested with sample diluent;
[0204] (2) The positive control serum was diluted 1:10,000 with sample diluent, and the negative control serum was diluted 1:200 with sample diluent;
[0205] (3) Sample loading: Add the serially diluted serum samples to be tested, negative control serum, positive control serum and blank control solution (sample diluent is used as blank control) to the pre-F ELISA plate at 100 μl / well, with the serum samples to be tested added to 1 well and the control solution added to 2 wells; add the sample diluent to the IgG-UNLB ELISA plate at 100 μl / well;
[0206] (4) Incubation: Incubate the ELISA plate at 37°C for 30 min and wash the plate five times with washing buffer in an automatic plate washer;
[0207] (5) Add enzyme: Add 100 μl / well of enzyme-labeled secondary antibody (HRP Goat Anti-Mouse IgG (H+L), ABclonal) to the ELISA plate, incubate at 37°C for 30 min, and wash the plate five times with washing buffer in an automatic plate washer;
[0208] (6) Color development: Mix equal volumes of color development solution A and color development solution B (Feijing Biotechnology), add 100 μl / well to the ELISA plate, and incubate at room temperature in the dark for 15 min;
[0209] (7) Termination: Add 50 μl / well of stop solution to terminate the reaction;
[0210] (8) Plate reading: Use an ELISA reader to measure the absorbance at a wavelength of 450 nm (reference wavelength is 620 nm). The results are shown in the following table and Figure 5 , Figure 6 shown.
[0211] Table 18. (3-week serum) Pre-F specific IgG content
[0212]
[0213] Table 19. (5-week serum) Pre-F specific IgG content
[0214]
[0215]
[0216] The results showed that significant Pre-F IgG antibodies were detected in the sera of animals immunized with each group of immunogens and adjuvants, and after the booster immunization on the 21st day, the Pre-F IgG GMC (geometric mean concentration) detected in the 5-week sera of each group of mice increased significantly to varying degrees. Although the binding antibodies have not yet established an immune correlation with protection, high concentrations of serum antibodies are associated with a significant reduction in the risk of severe lower respiratory tract disease after infection.
[0217] 11.2 Neutralizing Antibody Detection:
[0218] Neutralizing antibodies are indicators of immune effects that can specifically recognize antigen neutralizing sites on the surface of the virus, prevent the virus from invading cells and multiplying, and protect the body from harm. They have real antiviral effects. Zhongke Guobang was commissioned to use the RSVA2 strain to perform neutralizing antibody testing through the fluorescent spot reduction neutralization test (FRNT method). The specific steps are:
[0219] (1) Sample preparation: serum stored at -20°C was thawed at room temperature, heat inactivated at 56°C for 30 min, taken out after 30 min and cooled to room temperature, and then the six serum samples in each group were fully mixed to obtain mixed serum samples for each group.
[0220] (2) Sample loading and dilution: 40-fold initial dilution, followed by 4-fold dilution, for 6 dilutions. Take a 96-well plate, use the second column as the cell control (CC), and the third column as the virus control (VC). Add the 20-fold diluted sample to wells B4-B11, use a multichannel pipette to gently mix the liquid in wells B4-B11, and then perform a 4-fold dilution until wells G4-G11. Take the positive reference and negative reference for loading and dilution.
[0221] (3) Virus dilution: Dilute the virus to 800-1200 FFU / well on ice and add to each well except the cell control.
[0222] (4) Place the above 96-well plate in a 37°C, 5% CO2 incubator and incubate for 1 hour.
[0223] (5) HEp-2 cells were digested and counted and adjusted to 2.0×10 using complete culture medium. 5 pcs / mL, 100 μL / well was added into a 96-well plate.
[0224] (6) The cells were cultured in a 37° C., 5% CO 2 incubator. After 24-28 hours, GFP fluorescent spots were counted using a cell imaging multifunctional microplate detection system and the results were recorded.
[0225] (7) 50% neutralizing antibody inhibition rate (ND 50 ) calculation: the fluorescence spot value read by the instrument is input into the data analysis template, and the 50% neutralizing antibody inhibition rate (ND 50 The results are shown in the following table and Figure 7 , Figure 8 shown.
[0226] Table 20. Neutralizing antibody titers
[0227]
[0228] The results showed that significant neutralizing antibodies against RSV A2 strain were detected in the sera of animals immunized with each group of immunogens and adjuvants. Compared with the control group, mice induced to produce more neutralizing antibodies after 3 weeks of basic immunization with candidate antigens F142 and F144, especially the neutralizing antibody titer induced by F144 (ND 50 =960) was much higher than the positive control groups. After booster immunization, the neutralizing antibodies induced by candidate antigen F142 were detected in the 5-week serum of mice, which was comparable to the DS-Cav1, pXCS847 and PreF-1345 positive control groups, with no statistical difference, and much higher than the WT group and PreF-NP group. After immunization with candidate antigen F144, the neutralizing antibody titer induced by candidate antigen F144 was significantly higher than that of the positive control groups (ND 50 =14363), showing significant vaccine protection in both primary and booster immunizations.
[0229] It can be seen from the above experiments that the particle antigens, combined mutant particle antigens and vaccine compositions provided by the present invention can induce the production of high-titer neutralizing antibodies against RSV virus, which also suggests that the vaccine will provide better protective effects when the virus invades, which is of great significance to the research and development of RSV candidate vaccines.
[0230] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A recombinant respiratory syncytial virus particle antigen, comprising a granulation domain that can self-assemble into a dodecamer and a head domain of RSV F protein recombinant, wherein the head domain of the recombinant comprises an F1 domain truncated fragment and an F2 domain truncated fragment of RSV F protein directly connected or connected by a linker sequence from N-terminus to C-terminus, the F1 domain truncated fragment and the F2 domain truncated fragment corresponding to amino acid residues 146-306 and 51-104 of wild-type RSV F protein, respectively, and the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO:
1.
2. The particulate antigen as described in claim 1, wherein the C-terminus of the granulation domain is directly connected to the N-terminus of the recombinant head domain or is connected via a linker sequence, or the N-terminus of the granulation domain is directly connected to the C-terminus of the recombinant head domain or is connected via a linker sequence.
3. The particulate antigen according to claim 2, wherein the particulation domain is Dps. The particulate antigen according to claim 3 , wherein the Dps is derived from bacteria. The particulate antigen according to claim 4 , wherein the bacterium is Escherichia coli.
6. The particle antigen according to any one of claims 1 to 5, wherein the recombinant head domain is mutated compared to the head domain of the wild-type RSV F protein, the mutation being: composition: (A) Non-native disulfide bond mutations S55C+L188C and I148C+Y286C; (B) Cavity filling mutations: N67F and S190V; (C) Natural substitution: P102A.
7. The particulate antigen of claim 6, wherein the non-native disulfide bond mutation further comprises H159C+I291C.
8. The particulate antigen of claim 6, wherein the cavity-filling mutation further comprises V296F.
9. The particle antigen as claimed in claim 8, further comprising an electrostatic mutation G184N.
10. The particulate antigen of claim 9, wherein the non-native disulfide bond mutation further comprises H159C+I291C.
11. The particulate antigen of any one of claims 1-5, 6, 7-10, wherein the particulate antigen displays the F protein polypeptide in a pre-fusion conformation on the surface of a dodecamer nanoparticle.
12. Use of the particulate antigen according to any one of claims 1-5, 6, 7-10 in the preparation of a vaccine for preventing RSV infection.
13. A vaccine for preventing RSV infection, comprising the particle antigen of any one of claims 1-5, 6, 7-10; the vaccine provides protection against infection by at least one of RSV subtype A and / or subtype B.
Citation Information
Patent Citations
RSV-specific binding molecules and means for producing them
CN101778866B
RSV f protein mutants
CN108738312A
Antigenic respiratory syncytial virus polypeptides
CN112512567A
Respiratory virus immune composition
CN115103682A
Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20060159695A1
Cited By
Recombinant RSV f protein and use thereof
WO2025200576A1
